( idate;whether H5N1 or other strains of...)Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine,Health

idate; whether H5N1 or other strains of avian influenza will emerge as pandemic threats; whether the company's DNA vaccine candidate will be effective in protecting humans against H5N1 or other strains of avian influenza; whether the influenza vaccine or any other product candidates will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vaxfectin(TM) will provide a dose-sparing effect with the government-stockpiled H5N1 pandemic influenza vaccine; whether Vaxfectin(TM) will be used with other protein-based vaccines; whether Vical or its collaborative partners will seek or gain approval to market the influenza vaccine or any other product candidates; whether Vical or its collaborative partners will succeed in marketing the influenza vaccine or any other product candidates; whether the company's issued patents will be challenged and whether such challenges will have an adverse effect on the scope of the patents; whether the company will enforce its issued patents or will be successful in any enforcement efforts; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

    Contacts:   Investors:                   Media:

                Alan R. Engbring             Susan Neath

                Vical Incorporated           Porter Novelli Life Sciences

                (858) 646-1127               (619) 849-6007

                Website:  www.vical.com

CONTACT: Investors, Alan R. Engbring of Vical Incorporated,+1-858-646-1127; or Media, Susan Neath of Porter Novelli Life Sciences,+1-619-849-6007, for Vical Incorporated

Web site: http://www.vical.
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
8. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
9. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
10. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results